Actively Recruiting
Phase II Study of ZL-82 Tablets for Treating Moderate to Severe Atopic Dermatitis in Adults
Led by Chengdu Zenitar Biomedical Technology Co., Ltd · Updated on 2026-02-04
111
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of ZL-82 tablets to treat moderate to severe atopic dermatitis in adults aged 18 to 75 years. The study aims to understand whether ZL-82 tablets can improve the Eczema Area and Severity Index EASI scores and to assess the safety and tolerability of the drug. Participants will be compared to a placebo group to observe differences in treatment effects and physical outcomes. Participants are randomly assigned to one of three groups a high-dose ZL-82 tablet group taking 200 mg once daily, a low-dose ZL-82 tablet group taking 100 mg once daily, and a placebo group taking two tablets once daily. The treatment period lasts for 16 weeks, during which participants will take their assigned tablets daily and have check-ups every two weeks. They will also record their symptoms and the percentage change in their EASI scores compared to baseline. During the study, participants will undergo frequent assessments including health checkups, vital signs, laboratory tests, and electrocardiograms at multiple time points from screening through day 141. Blood concentrations of ZL-82 will be monitored on several days. Researchers will evaluate changes in EASI scores, Investigators Global Assessment IGA, pruritus rating scales, body surface area affected by dermatitis, quality of life, and patient self-assessments to measure outcomes. Safety will be monitored throughout, with adverse events tracked up to 20 weeks after treatment begins.
CONDITIONS
Brief Title
A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis
Research Team
W
Wang Fangmei
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here